Skip to main content
RecallFDAfda-F-1816-2018UNDECLARED ALLERGEN

FP0391 Confidence, Glucosamine Plus, With Hyaluronic Acid + Curcumin & Boswellia, 60 Extended Release Tablets, UPC: 8 92483 00106 9

Category
Units Affected
5,650
Recall Date
July 26, 2018
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1816-2018.

Product contains undeclared ingredients, Hydroxypropyl Methylcellulose (HPMC), Titanium Dioxide, Polyethylene Glycol (PEG), Triacetin.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1816-2018.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Confidence Inc./confidence U.s.a. Inc. or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1816-2018.

Confidence Inc./Confidence U.S.A. Inc.

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Confidence Inc./confidence U.s.a. Inc. Recall FAQ

Confidence Inc./confidence U.s.a. Inc. is the subject of a food safety report: FP0391 Confidence, Glucosamine Plus, With Hyaluronic Acid + Curcumin & Boswellia, 60 Extended Release Tablets, UPC: 8 92483 00106 9. The notice was published on July 26, 2018 by the U.S. Food and Drug Administration (FDA). Approximately 5,650 units are potentially affected.